FibroGen competitors

FibroGen Competitors include GlaxoSmithKline, Bristol-Myers Squibb, AstraZeneca and RubrYc Therapeutics.
Add company...
FibroGen
FibroGen
FibroGen is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics to treat serious unmet medical needs.
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline is a science-led healthcare company.
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
AstraZeneca
AstraZeneca
AstraZeneca, a global pharmaceutical company, discovers, develops, manufactures and markets prescription medicines.
RubrYc Therapeutics
RubrYc Therapeutics
RubrYc Therapeutics is a biotechnology solutions company using disruptive innovation to deliver fresh insights into the design and development of therapeutic antibodies.
Founding Date
Founding Date
1993
Founding Date
2000
Founding Date
1887
Founding Date
1999
Founding Date
2017
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Private
Tags
Locations
Locations
San Francisco, US HQ
Locations
Brentford, GB HQ
Locations
New York, US HQ
Vienna, AT
Braine L'alleud, BE
Calgary, CA
Edmonton, CA
Montreal, CA
Toronto, CA
see more
Locations
Cambridge, GB HQ
Sydney, AU
Brussels, BE
Fredericton, CA
Hamilton, CA
Mississauga, CA
Montreal, CA
see more
Locations
San Ramon, US HQ
Employees
Employees
42316% increase
Employees
98,462
Employees
23,700
Employees
61,100
Employees
N/A
Valuation ($)
Valuation ($)
3.5 b
Valuation ($)
101.9 b
Valuation ($)
87.2 b
Valuation ($)
98.6 b
Valuation ($)
N/A
Twitter followers
Twitter followers
N/A
Twitter followers
163.4 k
Twitter followers
120.8 k
Twitter followers
141.3 k
Twitter followers
N/A

Financial

Revenue (est.)
Revenue (est.)
$125.7m (FY, 2017)
Revenue (est.)
£30.2b (FY, 2017)
Revenue (est.)
$20.8b (FY, 2017)
Revenue (est.)
£22.5b (FY, 2017)
Revenue (est.)
N/A
Cost of goods
Cost of goods
N/A
Cost of goods
£10.3b (FY, 2017)
Cost of goods
$6.1b (FY, 2017)
Cost of goods
£4.3b (FY, 2017)
Cost of goods
N/A
Gross profit
Gross profit
N/A
Gross profit
£19.8b (FY, 2017)
Gross profit
$14.7b (FY, 2017)
Gross profit
£18.1b (FY, 2017)
Gross profit
N/A
Net income
Net income
($126.2m) (FY, 2017)
Net income
£2.2b (FY, 2017)
Net income
$975m (FY, 2017)
Net income
£2.9b (FY, 2017)
Net income
N/A

Operating

Countries
Countries
N/A
Countries
100 (FY, 2016)
Countries
N/A
Countries
100 (FY, 2016)
Countries
N/A
Phase II Trials Products
Phase II Trials Products
1 (FY, 2016)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
36 (FY, 2016)
Phase II Trials Products
N/A
Phase III Trials Products
Phase III Trials Products
1 (FY, 2016)
Phase III Trials Products
N/A
Phase III Trials Products
8 (FY, 2016)
Phase III Trials Products
27 (FY, 2016)
Phase III Trials Products
N/A
Projects in R&D Pipeline
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
44 (FY, 2016)
Projects in R&D Pipeline
132 (FY, 2016)
Projects in R&D Pipeline
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 15.5m
Total funding raised
N/A
Total funding raised
$ 10m
For sources of this data, please see the company profileDownload Excel

View company profiles

GlaxoSmithKline
HQ
Brentford, GB
Employees
98,462

GlaxoSmithKline is a science-led healthcare company.

View company
Bristol-Myers Squibb
HQ
New York, US
Employees
23,700

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

View company
AstraZeneca
HQ
Cambridge, GB
Employees
61,100

AstraZeneca, a global pharmaceutical company, discovers, develops, manufactures and markets prescription medicines.

View company
RubrYc Therapeutics
HQ
San Ramon, US

RubrYc Therapeutics is a biotechnology solutions company using disruptive innovation to deliver fresh insights into the design and development of therapeutic antibodies.

View company